Arcturus Therapeutics (ARCT) Misses Q4 EPS by 92c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Arcturus Therapeutics (ARCT) PT Lowered to $65 at Leerink Partners
March 7, 2025 5:47 AM ESTLeerink Partners analyst Lili Nsongo lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $65.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Today after close, ARCT reported FY24 earnings and provided a pipeline update. In the partnered vaccine... More
